Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant (HCT)

NCT04390113 is registered in ClinicalTrials.gov with AlloVir as lead sponsor.

NCT NCT04390113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04390113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant (HCT)
Lead sponsor
AlloVir
Phase
Phase 3
Overall status
Terminated
Start date
March 18, 2021
Completion date
January 30, 2024
Enrollment
97 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

bk virus infection, hemorrhagic cystitis